Simplifed lenacapavir dosing: PK results in HIV negative study
3 August 2022. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Conference reports
Doxycycline PEP significantly reduces STIs in people at high risk of infections
3 August 2022. Related: Conference reports, Coinfections and complications.
Another possible HIV cure case after stem cell transplantation for cancer; example of extended post-treatment control in Spain
3 August 2022. Related: Conference reports, Cure-related research.
Other cure-related sessions at AIDS 2022
3 August 2022. Related: Conference reports, Cure-related research.
Selected reports launched at AIDS 2022
3 August 2022. Related: Conference reports, On the web.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): final report
1 July 2022. Related: Conference reports.
CROI 2022: NAMSAL study comparing DTG to EFV400 in Cameroon: week 192 results
1 July 2022. Related: Conference reports, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): further reports
1 June 2022. Related: Conference reports.
CROI 2022: Updates from the VESTED study
1 June 2022. Related: Conference reports, Treatment strategies.
CROI 2022: Switching to dolutegravir for adults on stable PI-based second-line ART
1 June 2022. Related: Conference reports, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports
2 May 2022. Related: Conference reports.
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
CROI 2022: Other COVID-19 studies
2 May 2022. Related: Conference reports, Coinfections and complications, COVID-19.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports
1 April 2022. Related: Conference reports.
CROI 2022: Webcasts now online and open access
1 April 2022. Related: Conference reports.
CROI 2022: Islatravir studies for HIV treatment and PrEP
1 April 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses
1 April 2022. Related: Conference reports, Coinfections and complications, COVID-19: long COVID, COVID-19.
CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART in the REPRIEVE study
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: UK study shows PEP is started earlier using home starter packs
1 April 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: Summary of 14 key studies on HIV and liver disease
1 April 2022. Related: Conference reports, Hepatitis coinfection.
CROI 2022: Genomic entrapment of HIV in people on long-term ART, chimeric antigen receptor T cells and more on bNAbs
1 April 2022. Related: Conference reports, Cure-related research.
29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports
1 March 2022. Related: Conference reports.
CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Injectable CAB/RPV-LA results after three years follow-up
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Fourth potential stem cell HIV cure – in a US woman using donor cord cells
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Targetting reservoir with ART + bNAb 3BNC117 + romidepsin maintained undetectable viral load off-ART for 3.7 years in one case
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
1 March 2022. Related: Conference reports, Paediatric care, Cure-related research.
CROI 2022: AAV8-VRC07 vaccine generates new bNAb production in HIV positive people for up to three years
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: No impact from high-dose vitamin D3 on reducing the HIV viral reservoir
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana
1 March 2022. Related: Conference reports, Women's health, Pregnancy.
CROI 2022: ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV
1 March 2022. Related: Conference reports, Cancer and HIV.
CROI 2022: Other studies on anal cancer
1 March 2022. Related: Conference reports, Cancer and HIV.
CROI 2022: Telomere shortening associated with TAF but not TDF in CHARTER study
1 March 2022. Related: Conference reports, Basic science and immunology, Ageing and life expectancy.
CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: Long-acting doravirine implants as PrEP to prevent vaginal HIV transmission in mouse study
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: LEAP Workshop online: research into long-acting drugs
1 March 2022. Related: Conference reports, On the web.
CROI 2022 to only be virtual: programme online
7 February 2022. Related: Conference reports.
18th International European AIDS Conference (EACS 2021)
20 December 2021. Related: Conference reports.
EACS case study: how to diagnose HIV on PrEP – stopping PrEP or intensify to ART?
20 December 2021. Related: Conference reports, HIV prevention and transmission.
European AIDS Clinical Society honours Simon Collins for longstanding contribution to the field of HIV
20 December 2021. Related: Conference reports, Treatment advocacy.
18th International European AIDS Conference (EACS 2021)
30 November 2021. Related: Conference reports.
Lenacapavir: drug resistance after viral rebound in treatment experienced participants
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.
Implications of historical M184V on use of dual dolutegravir/lamivudine ART
30 November 2021. Related: Conference reports, Antiretrovirals, Drug resistance.
Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants didn’t restart oral ART within eight weeks
30 November 2021. Related: Conference reports, Antiretrovirals.
Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study
30 November 2021. Related: Conference reports, Antiretrovirals.
HIV-specific mental health services across the EU
30 November 2021. Related: Conference reports, Coinfections and complications.
18th International European AIDS Conference (EACS 2021)
31 October 2021. Related: Conference reports.
EACS 2021: a call for collaborations and for both HIV and COVID-19
31 October 2021. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Reduced responses to COVID-19 vaccines at low CD4 counts
31 October 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
EACS Guidelines: 11th edition (October 2021)
31 October 2021. Related: Conference reports, Guidelines.
Community “Respect my HIV” march: 30 October 2021 in London
31 October 2021. Related: Conference reports, Treatment advocacy.
11th IAS Conference on HIV Science (IAS 2021)
17 September 2021. Related: Conference reports.
IAS 2021 website now open access
17 September 2021. Related: Conference reports, On the web.
Substudies from the ODYSSEY trial: results July 2021
17 September 2021. Related: Conference reports, Paediatric care.
Trial design for next generation PrEP
17 September 2021. Related: Conference reports.
11th IAS Conference on HIV Science (IAS 2021)
1 August 2021. Related: Conference reports.
IAS 2021: lenacapavir studies show impressive results in naive, extensive drug resistance and potential as PrEP
1 August 2021. Related: Conference reports, Antiretrovirals.
IAS 2021: HIV pipeline drugs: CAB/RPV LA, fostemsavir, paediatric dolutegravir, lenacapavir, islatravir, MK-8507 and albuvirtide
1 August 2021. Related: Conference reports, Antiretrovirals.
IAS 2021: Proving efficacy of next generation PrEP: counterfactual controls in lenacapavir and islatravir studies
1 August 2021. Related: Conference reports, HIV prevention and transmission, Research studies.
IAS 2021: WHO report links HIV to 30% increased mortality from COVID-19: based on South African data
1 August 2021. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.